SCHEMBL3983033

SCHEMBL3983033

O=S(=O)(c1ccccn1)C(Cl)(Cl)Cl

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.50
PKM P14618 4/20 0.50
L3MBTL1 Q9Y468 1/20 0.43
NFE2L2 Q16236 3/20 0.40
ALDH1A1 P00352 3/20 0.40
MAPT P10636 1/20 0.40
SLC40A1 Q9NP59 2/20 0.39
MAOA P21397 1/20 0.39
MAOB P27338 1/20 0.39
LOX P28300 1/20 0.39
GLO1 Q04760 1/20 0.39
POLB P06746 3/20 0.39
KMT2A Q03164 2/20 0.39
MAPK1 P28482 1/20 0.39
TXNRD1 Q16881 1/20 0.39
LMNA P02545 2/20 0.39
TDP1 Q9NUW8 1/20 0.38
TSHR P16473 1/20 0.38
ATM Q13315 1/20 0.38
KEAP1 Q14145 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL542032 0.81 KDM4E (0.47) KDM4EPKML3MBTL1NFE2L2ALDH1A1
SCHEMBL6904752 0.81 KDM4E (0.47) KDM4EPKML3MBTL1NFE2L2ALDH1A1
SCHEMBL30528257 0.79 KDM4E (0.46) KDM4EPKML3MBTL1NFE2L2SLC40A1
SCHEMBL24995386 0.79 KDM4E (0.46) KDM4EPKML3MBTL1NFE2L2ALDH1A1
SCHEMBL6476899 0.79 KDM4E (0.46) KDM4EPKML3MBTL1NFE2L2SLC40A1
SCHEMBL25376162 0.76 NFE2L2 (0.45) KDM4EPKML3MBTL1NFE2L2ALDH1A1
SCHEMBL25377920 0.76 PKM (0.43) KDM4EPKML3MBTL1NFE2L2SLC40A1
SCHEMBL29650217 0.76 KDM4E (0.55) KDM4EPKML3MBTL1NFE2L2ALDH1A1
SCHEMBL23025 0.76 KDM4E (0.55) KDM4EPKML3MBTL1NFE2L2ALDH1A1
SCHEMBL14354597 0.76 CYP3A4 (0.37) ALDH1A1LOXTDP1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2003116-A9 PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES Takeda Pharmaceutical Company Limited (JP) 2009-05-20 EP disclosed
US-20090054655-A1 Process for the Production of Organic Oxides TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-02-26 US disclosed
EP-2003116-A2 PROCESS FOR THE PRODUCTION OF ORGANIC OXIDES Takeda Pharmaceutical Company Limited (JP) 2008-12-17 EP disclosed
US-20070281246-A1 Processing method of light sensitive planographic printing plate material KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-12-06 US disclosed
US-20070281246-A1 Processing method of light sensitive planographic printing plate material KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-12-06 US disclosed
US-7220530-B2 Light sensitive planographic printing plate material KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-05-22 US disclosed
US-7220530-B2 Light sensitive planographic printing plate material KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-05-22 US disclosed
US-7172851-B2 Light sensitive composition, planographic printing plate material, and image formation method KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-02-06 US disclosed
US-7172851-B2 Light sensitive composition, planographic printing plate material, and image formation method KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-02-06 US disclosed
US-7169535-B2 Photosensitive composition and photosensitive lithographic printing plate KONICA MINOLTA HOLDINGS, INC. (JP) 2007-01-30 US disclosed
US-7169535-B2 Photosensitive composition and photosensitive lithographic printing plate KONICA MINOLTA HOLDINGS, INC. (JP) 2007-01-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054655-A1 Process for the Production of Organic Oxides OXSR1, CBR3, CYB5R3 KDM4E 2423/4885PKM 3357/4885L3MBTL1 3917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.